FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lismore Damian T. 		2. Issuer Name and Ticker or Trading Symbol

Nexvet Biopharma plc [ NVET ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O NEXVET BIOPHARMA PLC, UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2017
(Street)

TULLAMORE, L2 R35 FR98
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares   7/1/2017     M    13750   A $.125   47500   D  
 
Ordinary Shares   7/1/2017     M    16250   A $.125   63750   D  
 
Ordinary Shares   7/1/2017     M    4000   A $.125   67750   D  
 
Ordinary Shares   7/1/2017     M    7079   A $.125   21239   I   By spouse  
Ordinary Shares                  18724   I   Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units   $.125   9/5/2016     M         65000    7/1/2017   (2) 7/1/2020   Ordinary Shares   13750   $0   27500   D  
 
Restricted Share Units   $.125   7/1/2017     M         16250    7/1/2017   (3) 7/1/2021   Ordinary Shares   16250   $0   48750   D  
 
Option to Purchase Shares   $.125   7/1/2017     M         4000    7/1/2017   7/1/2019   Ordinary Shares   4000   $0   0   D  
 
Option to Purchase Shares   $.125   7/1/2017     M         7079    11/5/2016   11/5/2023   Ordinary Shares   7079   $0   0   I   By spouse  

Explanation of Responses:
(1)  The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
(2)  13,750 of the Restricted Share Units vested and became convertible on 7/1/17 and 13,750 of the Restricted Share Units will vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
(3)  16,250 of the Restricted Share Units vested and became convertible on 7/1/17 and 16,250 of the Restricted Share Units will vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lismore Damian T.
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE, L2 R35 FR98

Chief Financial Officer

Signatures
/s/ Damian Lismore by Geraldine T. Farrell, Attorney-in-Fact 7/3/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 NEXVET BIOPHARMA PLC 차트를 더 보려면 여기를 클릭.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 NEXVET BIOPHARMA PLC 차트를 더 보려면 여기를 클릭.